Depression in Parkinson's Disease: An Update

Current Clinical Neurology

Volumn 24, Issue , 2013, Pages 3-15

  Benton, Jeana L ^a   Wengel, Steven P ^a   Burke, William J ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Depression; Dysthymia; Electroconvulsive therapy; Mania; Mesocorticolimbic pathway; Nortriptyline; Parkinson's disease; Paroxetine; Pramipexole; Selective serotonin reuptake inhibitor; Subthalamic nucleus deep brain stimulation; Tricyclic anti depressant

Indexed keywords

AMFEBUTAMONE; BROMOCRIPTINE; CITALOPRAM; DESIPRAMINE; DOPAMINE; LEVODOPA; MIRTAZAPINE; NORTRIPTYLINE; PAROXETINE; PERGOLIDE; RASAGILINE; SELEGILINE; SERTRALINE;

BRAIN DEPTH STIMULATION; CENTRAL NERVOUS SYSTEM FUNCTION; CLINICAL ASSESSMENT; COGNITION; DEPRESSION; DIAGNOSTIC PROCEDURE; DISEASE ASSOCIATION; DISEASE COURSE; DYSTHYMIA; ELECTROCONVULSIVE THERAPY; EMOTIONAL DISORDER; GENERAL HEALTH QUESTIONNAIRE; HUMAN; MANIA; META ANALYSIS (TOPIC); MINI MENTAL STATE EXAMINATION; MOOD CHANGE; PARKINSON DISEASE; PATHOLOGY; PREVALENCE; PRIORITY JOURNAL; PSYCHOSOCIAL CARE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; SYSTEMATIC REVIEW (TOPIC);

EID: 84899679481     PISSN: 15590585     EISSN: None     Source Type: Book Series    
DOI: None     Document Type: Review

References (114)

1. Kuhn W, Heye N, Muller TH, et al. The motor performance test series in Parkinson's disease is in fluenced by depression. J Neural Transm. 1996; 103: 349-54.
2. Schrag A, Jahanshahi M, Quinn N. What contributes to quality of life in patients with Parkinson's disease? J Neurol Neurosurg Psychiatry. 2000; 69: 308-12.
3. Weintraub D, Moberg PJ, Duda JE, Katz IR, Stern MB. Effect of psychiatric and other nonmotor symptoms on disability in Parkinson's disease. J Am Geriatr Soc. 2004; 52: 784-8.
4. Chen P, Kales HC, Weintraub D, et al. Depression in veterans with Parkinson's disease: frequency, comorbidity, and healthcare utilization. Int J Geriatr Psychiatry. 2007; 22: 543-8.
5. Reijnders JS, Uwe E, Weber WEJ, Aarsland D, Leentjens AFG. A systematic review of prevalence studies of depression in Parkinson's disease. Mov Disord. 2008; 23: 183-9.
6. Leentjens AFG. Depression in Parkinson's disease: conceptual issues and clinical challenges. J Geriatr Psychiatry Neurol. 2004; 17: 120-6.
7. Cummings JL. Depression and Parkinson's disease: a review. Am J Psychiatry. 1992; 149: 443-54.
8. Chen P, Kales HC, Weintraub D, Blow FC, Jiang L, Mellow AM. Antidepressant treatment of veterans with Parkinson's disease and depression. J Geriatr Psychiatry Neurol. 2007; 20(3): 161-5.
9. Tandberg E, Larsen JP, Aarsland D, Cummings JL. The occurrence of depression in Parkinson's disease. A community-based study. Arch Neurol. 1996; 53: 175-9.
10. Weintraub D. Diagnosing and treating depression in patients with Parkinson's disease. Psychiatric Ann. 2004; 34: 299-304.
11. Veazy C, Aki SOE, Cook KF, Lai EC, Kunik ME. Prevalence and treatment of depression in Parkinson's disease. J Neuropsychiatry Clin Neurosci. 2005; 17: 310-23.
12. Goldberg DP, William P. A user's guide to the General Health Questionnaire. Windsor: NFERNelson; 1988.
13. Hantz P, Caradoc-Davies G, Caradoc-Davies T, et al. Depression in Parkinson's disease. Am J Psychiatry. 1994; 151: 1010-4.
14. Folstein MF, Folstein SE, McHugh PR. "Mini-Mental State": a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975; 12: 189-98.
15. Starkstein SE, Preziosi TJ, Bolduc PL, Robinson RG. Depression in Parkinson's disease. J Nerv Ment Dis. 1990; 178: 27-31.
16. Celesia GG, Wanamaker WM. Psychiatric disturbances in Parkinson's disease. Dis Nerv Syst. 1976; 37: 123-5.
17. Brown R, Jahanshahi M. Depression in Parkinson's disease: a psychosocial viewpoint. Adv Neurol. 1995; 65: 61-84.
18. Starkstein SE, Berthier ML, Bolduc PL, et al. Depression in patients with early versus late onset Parkinson's disease. Neurology. 1989; 39: 1441-5.
19. Gotham AM, Brown RG, Marsden CD. Depression in Parkinson's disease: a quantitative and qualitative analysis. J Neurol Neurosurg Psychiatry. 1986; 49: 381-9.
20. Brown RC, MacCarthy B. Psychiatric morbidity in patients with Parkinson's disease. Psychol Med. 1990; 20: 77-87.
21. Huber SJ, Paulson GW, Shuttleworth EC. Depression in Parkinson's disease. Neuropsychiatry Neuropsychol Behav Neurol. 1988; 1: 47-51.
22. Jankovic J, McDermott M, Carter J, et al. Parkinson Study Group. Variable expression of Parkinson's disease: a baseline analysis of the DATATOP cohort. Neurology. 1990; 40: 1529-34.
23. Brown GL, Wilson WP. Parkinsonism and depression. South Med J. 1972; 65: 540-5.
24. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association; 1994.
25. Leentjens AFG, Marinus J, Van Hilten JJ, et al. The contribution of somatic symptoms to the diagnosis of depressive disorder in Parkinson's disease: a discriminant analytic approach. J Neuropsychiatry Clin Neurosci. 2003; 15: 74-7.
26. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960; 23: 56-62.
27. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979; 134: 382-9.
28. Marsh L, McDonald WM, Cummings J, Ravina B, the NINDS/NIMH Work Group on Depression and Parkinson's Disease. Provisional diagnostic criteria for depression in Parkinson's disease: report of an NINDS/NIMH Work Group. Mov Disord. 2006; 21: 148-58.
29. Burke WJ, Rubin EH, Morris J, Berg L. Symptoms of depression in dementia of the Alzheimer type. Alzheimer Dis Assoc Disord. 1988; 2: 356-62.
30. Gonera EG, van't Hof M, Berger HJ, et al. Symptoms and duration of the prodromal phase in Parkinson's disease. Mov Disord. 1997; 12: 871-6.
31. Schuurman AG, van den Akker M, Ensinck K, et al. Increased risk of Parkinson's disease after depression: a retrospective cohort study. Neurology. 2002; 58: 1501-4.
32. Leentjens AFG, Van den Akker M, Metsemakers JFM, Lousberg R, Verhey FRJ. Higher incidence of depression preceding the onset of Parkinson's disease: a register study. Mov Disord. 2003; 18: 414-8.
33. Ishihara L, Brayne C. A systematic review of depression and mental illness preceding Parkinson's disease. Acta Neurol Scand. 2006; 113: 211-20.
34. Krishnan KR, Delong M, Kraemer H, et al. Comorbidity of depression with other medical diseases in the elderly. Biol Psychiatry. 2002; 52: 559-88.
35. Nilsson FM, Kessing LV, Sorensen TM, et al. Major depressive disorder in Parkinson's disease: a register-based study. Acta Psychiatr Scand. 2002; 106: 202-11.
36. Leentjens AFG, Lousberg R, Verhey FJR. Markers for depression in Parkinson's disease. Acta Psychiatr Scand. 2002; 106: 196-201.
37. MacCarthy B, Brown RG. Psychosocial factors in Parkinson's disease. Br J Clin Psychol. 1989; 28: 41-52.
38. Oertel WH, Hoglinger GU, Caraceni T, et al. Depression in Parkinson's disease. Adv Neurol. 2001; 86: 373-83.
39. Mayeux R, Stern Y, Cote L, Williams BW. Altered serotonin metabolism in depressed patients with Parkinson's disease. Neurology. 1984; 34(5): 642-6.
40. Mayeux R. The "serotonergic hypothesis" for depression in Parkinson's disease. Adv Neurol. 1990; 53: 163-6.
41. Fibiger HC. The neurobiological substrates of depression in Parkinson's disease: a hypothesis. Can J Neurol Sci. 1984; 11: 105-7.
42. Price KS, Farley IJ, Hornykiewicz O. Neurochemistry of Parkinson's disease: relation between striatal and limbic dopamine. Adv Biochem Psychopharmacol. 1978; 19: 293-300.
43. Javoy-Agid F, Agid Y. Is the mesocortical dopaminergic system involved in Parkinson's disease? Neurology. 1980; 30: 1326-30.
44. Baxter Jr LR, Schwartz JM, Phelps ME, et al. Reduction of prefrontal cortex glucose metabolism common to three types of depression. Arch Gen Psychiatry. 1989; 46: 243-50.
45. Zarow C, Lyness SA, Mortimer JA, Chui HC. Neuronal loss is greater in the locus coeruleus than nucleus basalis and substantia nigra in Alzheimer and Parkinson Diseases. Arch Neurol. 2003; 60: 337-41.
46. Remy P, Doder M, Lees A, Turjanski N, Brooks D. Depression in Parkinson's disease: loss of dopamine and noradrenaline innervation in the limbic system. Brain. 2005; 128: 1314-22.
47. Bejjani BP, Damier P, Arnulf I, et al. Transient acute depression induced by high-frequency deep-brain stimulation. N Engl J Med. 1999; 340: 1476-80.
48. Alexopoulos G, Kiosses D, Klimstra S, Kalayam B, Bruce M. Clinical presentation of the "depressionexecutive dysfunction syndrome" of late life. Am J Geriatr Psychiatry. 2002; 10: 98-106.
49. Des Rosiers G. Primary or depressive dementia: mental status screening. Int J Neurosci. 1992; 64: 33-67.
50. LaRue A. Aging and neuropsychological assessment. New York: Plenum; 1992. p. 259-89.
51. Rosenstein LD. Differential diagnosis of the major progressive dementias and depression in middle and late adulthood: a summary of the literature of the early 1990s. Neuropsychol Rev. 1998; 8: 109-67.
52. Mayeux R. Depression in the patient with Parkinson's disease. J Clin Psychiatry. 1990; 51(suppl): 20-3.
53. Factor SA, Molho ES, Podskalny GD, Brown D. Parkinson's disease: drug-induced psychiatric states. Adv Neurol. 1995; 65: 115-38.
54. Barone P, Scarzella L, Marconi R, et al. For the Depression/Parkinson Italian Study Group. Pramipexole versus sertraline in the treatment of depression in Parkinson's disease: a national multicenter parallel-group randomized study. J Neurol. 2006; 253: 601-7.
55. Rektorova I, Rektor I, Bares M, et al. Pramipexole and pergolide in the treatment of depression in Parkinson's disease: a national multicentre prospective randomized study. Eur J Neurol. 2003; 10: 399-406.
56. Leentjens AFG, Koester J, Fruh B, Shephard DTS, Barone P, Houben JJG. The effect of pramipexole on mood and motivational symptoms in Parkinson's disease: a meta-analysis of placebo-controlled studies. Clin Ther. 2009; 31: 89-98.
57. Jouvent R, Abensour P, Bonnett AM, et al. Antiparkinsonian and antidepressant effects of high doses of bromocriptine: an independent comparison. J Affect Disord. 1983; 5: 141-5.
58. Allain H, Pollak P, Neukirch HC, et al. Symptomatic effect of selegiline in de novo parkinsonian patients: the French selegiline multicenter trial. Mov Disord. 1993; 8 Suppl 1: 36-40.
59. Steur ENHJ, Ballering LAP. Combined and selective monamine oxidase inhibition in the treatment of depression in Parkinson's disease. In: Stern GM, editor. Parkinson's disease: advances in neurology, vol. 80. Philadelphia, PA: Lippincott Williams & Wilkins; 1999. p. 505-8.
60. Thobois S, Mertens P, Guenot M, et al. Subthalamic nucleus stimulation in Parkinson's disease: clinical evaluation of 18 patients. J Neurol. 2002; 249: 529-34.
61. Krack P, Batir A, Blercom N, et al. Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson's disease. N Engl J Med. 2003; 349: 1925-34.
62. Herzog J, Volkmann J, Krack P, et al. Two-year follow-up of subthalamic deep brain stimulation in Parkinson's disease. Mov Disord. 2003; 18: 1332-7.
63. Martinez-Martin P, Valldeoriola F, Tolosa E, et al. Bilateral subthalamic nucleus stimulation and quality of life in advanced Parkinson's disease. Mov Disord. 2002; 17: 372-7.
64. Smeding HMM, Speelman JD, Koning-Haanstra M, Schuurman PR, Nijssen P, Van Laar T, Schmand B. Neuropsychological effects of bilateral STN stimulation in Parkinson's disease: a controlled study. Neurology. 2006; 66: 1830-6.
65. Deuschl G, Schade-Brittinger C, Krack P, et al. For the German Parkinson Study Group, Neurostimulation Section. A randomized trial of deep-brain stimulation for Parkinson's disease. N Engl J Med. 2006; 355: 896-908.
66. Funkiewiez A, Ardouin C, Krack P, et al. Acute psychotropic effects of bilateral subthalamic nucleus stimulation and levodopa in Parkinson's disease. Mov Disord. 2003; 18: 524-30.
67. Voon V, Krack P, Lang AE, et al. A multicentre study on suicide outcomes following subthalamic stimulation for Parkinson's disease. Brain. 2008; 131: 2720-8.
68. Soulas T, Gurruchaga JM, PalfiS, Cesaro P, Nguyen JP, Fenelon G. Attempted and completed suicides after subthalamic nucleus stimulation for Parkinson's disease. J Neurol Neurosurg Psychiatry. 2008; 79: 952-4.
69. Houeto JL, Mesnage V, Mallet L, et al. Behavioral disorders, Parkinson's disease and subthalamic stimulation. J Neurol Neurosurg Psychiatry. 2002; 72: 701-7.
70. Burkhard PR, Vingerhoets FJG, Berney A, Bogousslavsky J, Villemure JG, Ghika J. Suicide after successful deep brain stimulation for movement disorders. Neurology. 2004; 63: 2170-2.
71. Berney A, Vingerhoets F, Perrin A, et al. Effect on mood of subthalamic DBS for Parkinson's disease: a consecutive series of 24 patients. Neurology. 2002; 59: 1427-9.
72. Doshi PK, Chhaya N, Bhatt MH. Depression leading to attempted suicide after bilateral subthalamic nucleus stimulation for Parkinson's disease. Mov Disord. 2002; 17: 1084-100.
73. Romito LM, Raja M, Daniele A, et al. Transient mania with hypersexuality after surgery for highfrequency stimulation of the subthalamic nucleus in Parkinson's disease. Mov Disord. 2002; 17: 1371-4.
74. Kulisevsky J, Berthier ML, Gironell A, et al. Mania following deep brain stimulation for Parkinson's disease. Neurology. 2002; 59: 1421-4.
75. Witt K, Daniels C, Reiff J, et al. Neuropsychological and psychiatric changes after deep brain stimulation for Parkinson's disease: a randomized multicentre study. Lancet Neurol. 2008; 7: 605-14.
76. Myslobodsky M, Lalonde FM, Hicks L. Are patients with Parkinson's disease suicidal? J Geriatr Psychiatry Neurol. 2001; 14: 120-4.
77. Voon V, Krack P, Lang A, et al. Factors associated with suicide risk following STN DBS for Parkinson's disease. Mov Disord. 2006; 21 Suppl 15: S691.
78. Schlaepfer TE, Fins JJ. Deep brain stimulation and the neuroethics of responsible publishing, when one is not enough. JAMA. 2010; 303: 775-6.
79. Agid Y, Schupback M, Gargiulo M, et al. Neurosurgery in Parkinson's disease: the doctor is happy, the patient less so? J Neural Transm Suppl. 2006; 70: 409-14.
80. Voon V, Saint-Cyr J, Lozano AM, Moro E, Poon YY, Lang AE. Psychiatric symptoms in patients with Parkinson disease presenting for deep brain stimulation surgery. J Neurosurg. 2005; 103: 246-51.
81. Mendis T, Suchowersky O, Lang A, Gauthier S. Management of Parkinson's disease: a review of current and new therapies. Can J Neurol Sci. 1999; 26: 89-103.
82. Lieberman A. Managing the neuropsychiatric symptoms of Parkinson's disease. Neurology. 1998; 50: S33-8.
83. Poewe W, Seppi K. Treatment options for depression and psychosis in Parkinson's disease. J Neurol. 2001; 248 Suppl 3: III12-21.
84. Miyasaki JM, Shannon K, Voon V, et al. Practice parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson's disease (an evidence-based review): report of the quality standards subcommittee of the American academy of neurology. Neurology. 2006; 66: 996-1002.
85. Weintraub D, Morales KH, Moberg PJ, et al. Antidepressant studies in Parkinson's disease: a review and meta-analysis. Mov Disord. 2005; 20: 1161-9.
86. Menza M, Dobkin RD, Marin H, et al. A controlled trial of antidepressants in patients with Parkinson disease and depression. Neurology. 2009; 72: 886-92.
87. Leentjens AFG, Vreeling FW, Luijckx GJ, Verhey FRJ. SSRIs in the treatment of depression in Parkinson's disease. Int J Geriatr Psychiatry. 2003; 18: 552-4.
88. Menza M, Marin H, Kaufman K, Mark M, Lauritano M. Citalopram treatment of depression in Parkinson's disease: the impact on anxiety, disability, and cognition. J Neuropsychiatry Clin Neurosci. 2004; 16: 315-9.
89. Antonini A, Tesei S, Zecchinelli A, et al. Randomized study of sertraline and low-dose amitriptyline in patients with Parkinson's disease and depression: effect on quality of life. Mov Disord. 2006; 21: 1119-22.
90. Ceravolo R, Nuti A, Piccinni A, et al. Paroxetine in Parkinson's disease: effects on motor and depressive symptoms. Neurology. 2000; 55: 1216-8.
91. Tesei A, Antonini A, Canesi M, et al. Tolerability of paroxetine in Parkinson's disease: a prospective study. Mov Disord. 2000; 15: 986-9.
92. Dell'Agnello G, Ceravolo R, Nuti A, et al. SSRIs do not worsen Parkinson's disease: evidence from an open-label, prospective study. Clin Neuropharmacol. 2001; 24: 221-7.
93. Hauser RA, Zesiewicz TA. Sertraline for the treatment of depression in Parkinson's disease. Mov Disord. 1997; 12: 756-9.
94. Weintraub D, Taraborelli D, Morales K, Duda JE, Katz IR, Stern MB. Escitalopram for major depression in Parkinson's disease: an open-label, flexibledosage study. J Neuropsychiatry Clin Neurosci. 2006; 18: 377-83.
95. Wermuth L, Sorensen PS, Timm S, et al. Depression in idiopathic Parkinson's disease treated with citalopram. Nord J Psychiatry. 1998; 52: 163-9.
96. Andersen J, Aabro E, Gullmann N, et al. Antidepressive treatment in Parkinson's disease: a controlled trial of the effect of nortriptyline in patients with Parkinson's disease treated with l-dopa. Acta Neurol Scand. 1980; 62: 210-9.
97. Laitinen L. Desipramine in the treatment of Parkinson's disease: a placebo-controlled study. Acta Neurol Scand. 1969; 45: 109-13.
98. Devos D, Dujardin K, Poirot I, et al. Comparison of desipramine and citalopram treatments for depression in Parkinson's disease: a double-blind, randomized, placebo-controlled study. Mov Disord. 2008; 23: 850-7.
99. Ritter JL, Alexander B. Retrospective study of selegiline-antidepressant drug interactions and a review of the literature. Ann Clin Psychiatry. 1997; 9: 7-13.
100. Richard IH, Kurlan R, Tanner C, et al. Serotonin syndrome and the combined use of deprenyl and an antidepressant in Parkinson's disease. Neurology. 1997; 48: 1070-7.
101. Djaldetti R, Yust-Katz S, Kolianov V, Melamed E, Dabby R. The effect of duloxetine on primary pain symptoms in Parkinson disease. Clin Neuropharmacol. 2007; 30: 201-5.
102. Onofrj M, Luciano AL, Thomas A, et al. Mirtazapine induces REM sleep behavior disorder (RBD) in Parkinsonism. Neurology. 2003; 60: 113-5.
103. The American Psychiatric Association practice guidelines: major depressive disorder. 2nd ed. http://www. psychiatryonine. com/pracGuide/pracGuide Topic_7. aspx. Accessed 1 Mar 2010.
104. Burke WJ, Peterson J, Rubin EH. Electroconvulsive therapy in the treatment of combined depression and Parkinson's disease. Psychosomatics. 1988; 29: 341-6.
105. Popeo D, Kellner CH. ECT for Parkinson's disease. Med Hypotheses. 2009; 73: 468-9.
106. Wengel SP, Burke WJ, Pfeiffer RF, et al. Maintenance electroconvulsive therapy for intractable Parkinson's disease. Am J Geriatr Psychiatry. 1998; 6: 263-9.
107. Andersen K, Balldin J, Gottfries CG, et al. A doubleblind evaluation of electroconvulsive therapy in Parkinson's disease with "on-off" phenomena. Acta Neurol Scand. 1987; 76: 191-9.
108. Shulman R. Maintenance ECT in the treatment of PD: therapy improves psychotic symptoms, physical function. Geriatrics. 2003; 58: 43-5.
109. Aarsland D, Larsen JP, Waage O, Langeveld JH. Maintenance electroconvulsive therapy for Parkinson's disease. Convuls Ther. 1997; 13: 274-7.
110. Fall PA, Granerus AK. Maintenance ECT in Parkinson's disease. J Neural Transm. 1999; 106: 737-41.
111. Bailine S, Kremen N, Kohen I, et al. Bitemporal electroconvulsive therapy for depression in a Parkinson disease patient with a deep-brain stimulator. J ECT. 2008; 24: 171-2.
112. Chou KL, Hurtig HI, Jaggi JL, Baltuch GH, Pelchat RJ, Weintraub D. Electroconvulsive therapy for depression in a Parkinson's disease patient with bilateral subthalamic nucleus deep brain stimulators. Parkinsonism Relat Disord. 2005; 11: 403-6.
113. Moscarillo FM, Annunziata CM. ECT in a patient with a deep brain stimulating electrode in place. J ECT. 2000; 16: 287-90.
114. Rasmussen K, Abrams R. Treatment of Parkinson's disease with electroconvulsive therapy. Psychiatr Clin North Am. 1991; 14: 925-33.